Spago Nanomedical has received notice from the United States Patent and Trademark Office (USPTO) that it intends to grant the company’s patent application including a critical component of the SpagoPix candidate drug SN132D.
The patent will be granted following confirmation of Spago Nanomedical and payment of applicable fees, states the company. The granted patent is titled “Chemical Compounds for Coating of Nanostructures”. The patent contains claims for the proprietary coating material that is part of the company’s nanoparticles.
The granted patent provides extended market exclusivity for SpagoPix in USA until at least 2038.
The patent was previously granted in Europe and Japan, and further approvals in additional countries are expected.